Loading
A phase 3 trial of Adaptive radiotherapy in Rectal cancer, run by Shandong Cancer Hospital and Institute, active and no longer recruiting.
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer is a phase 3 interventional study registered as NCT06246344 by Shandong Cancer Hospital and Institute, with 128 participants planned, started 2023-12-01 and due to reach its primary completion in 2025-12-01. Interventions recorded: Online Adaptive Radiotherapy With Sequential Boost, Conventional Non-Adaptive IMRT, Capecitabine, CAPEOX, Total Mesorectal Excision. Conditions recorded: Rectal Cancer.
Linked to the technology Adaptive radiotherapy because the registry names it ("adaptive radiotherapy") among its interventions and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
Shares Capecitabine, Rectal cancer and the tag pipeline.
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Capecitabine and the tag pipeline.
Shares Capecitabine and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Capecitabine and the tag pipeline.